10-YEARS EXPERIENCE OF ETANERCEPT USE IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS IN CHELYABINSK REGIONAL PEDIATRIC HOSPITAL

Galina Glazyrina1,2, Olga Sudareva3. 1South Ural State Medical University, Chelyabinsk, Russian Federation; 2Chelyabinsk regional pediatric hospital, Chelyabinsk, Russian Federation; 3Chelyabinsk regional pediatric hospital, Chelyabinsk, Russian Federation

Background: Juvenile idiopathic arthritis (JIA) in recent decades has changed its course, thanks to the use of genetically engineered biological drugs. If therapy with methotrexate is inefficient etanercept is the drug of choice for JIA treatment. Etanercept has been used in Chelyabinsk regional pediatric hospital during 10 years.


Methods: 51 children aged from 3 to 17 (mean age 10.0 years) diagnosed with JIA were under monitoring (12 boys, 39 girls). Disease duration was from 2 to 15 years (mean duration 5.4 years). JIA was diagnosed based on ILAR diagnostic criteria. Oligo arthritis was diagnosed in children, mono- and polyarticular arthritis was diagnosed in 34 children. 3 patients had systemic JIA (without active systemic presentations), 4 children were diagnosed with JIA were under monitoring (12 boys, 39 girls). Disease duration was from 3 months to 9 years (mean duration 29 months).

Results: Prior to etanercept use high disease activity was observed in all children. Mean number of joints with active arthritis was 8 [4;10] (Me[25,75%]). Mean number of joints with functional impairments – 4 [2;10]. Mean ESR (according to Panchenkov) – 23 [10;35] mm/h, CRP 12.0 [5.7;32] g/L. Assessment of functional activity according to CHAQ questionnaire – 1.25 [1;2]. Activity assessment according to VAS by doctor – 70 [60;70]. Assessment of parents/patients according to VAS 70 [60;80]. No active systemic presentations and eye lesions were found in children under monitoring.

On the background of etanercept therapy a decrease in disease activity was observed in 50 children. Mean number of joints with active arthritis was 0 [0;2] (Me[25,75%]). Mean number of joints with functional impairments – 0 [0;2] (P=0.0001). Mean ESR was 5 [3;6] mm/h (P<0.0001), CRP 3 [2;4] g/L (P<0.0001). Assessment of functional activity according to CHAQ questionnaire was 0.125 [0.05;0.25] (P<0.0001). Activity assessment according to VAS by doctor – 10 [5;20] (P<0.0001). Assessment of parents according to VAS 10 [5;20] (P<0.0001).

Clinical disease remission (according to ACR pedi criteria ≥90%) was observed in 52 patients after 6-12 months of treatment. Remission duration up to now is from 1 to 7 years. According to ACR criteria pedi remission was 70% in 11 children, 50% in 5, 30% in 2. Etanercept was well-tolerated. Drug was cancelled in 9 patients. 6 patient (11.8%) developed bilateral uveitis, one patient had an allergic reaction (rash), one - systemic manifestations, one - urinary tract infection. There were no cases of tuberculosis.

Conclusion: Etanercept therapy was highly effective and safe in patients with JIA. Clinical remission was achieved in 62.7% children. Decrease in disease activity was observed in 98% of children. 11.8% patient developed uveitis, on average, after a year of using etanercept.

REFERENCES


CENTRAL NERVOUS SYSTEM ANGIITIS: THE EXPERIENCE OF A TERTIARY RHEUMATOLOGY BRAZILIAN CENTER

Francisco Hugo Rodrigues Gomes1, Camila Maria Viana Batista2, Josè Sylvio Menezes Parentes1, Luana Coelho Benevides1, Milena Fozer Leite1, Virginia Ferri1, Luciana Martins de Carvalho1. 1University of São Paulo, Department of Pediatrics, Division of Pediatric Rheumatology, Ribeirão Preto, Brazil; 2University of São Paulo, Department of Pediatrics, Ribeirão Preto, Brazil

Background: Central nervous system (CNS) angiitis is a severe and rare inflammatory brain disease whose course varies from patient to patient. May be associated with infections, malignancies, metabolic diseases or systemic collagen vascular disorders. It is classified as primary or idiopathic in the absence of associated systemic diseases. The exact incidence is still undetermined.

Objectives: To describe the clinical and laboratory data, the response to therapy and outcome of patients with CNS angiitis seen at a Tertiary Pediatric Rheumatology Center.

Methods: This is a retrospective, single-center chart review study of pediatric patients with clinical diagnoses of CNS angiitis, followed up in a Tertiary Pediatric Rheumatology Center, from January 2009 to December 2018. Diagnosis was confirmed by magnetic resonance angiography (MRA) or after exhaustive exclusion of other causes.

Results: Nine patients (4 girls) were enrolled in this study. Mean age at inclusion and at diagnosis was 11.5 years (7.8 to 19.9) and 8 years (3.5 to 12.5), respectively. Among the 9 patients, 4(44%) were diagnosed with primary CNS angiitis. Polyarteritis nodosa (n=1), Polyvad Behçet disease (n=1) were the aetiologies of secondary CNS angiitis. Main clinical features were sudden onset of seizures (67%) and headache (55%). Other important symptoms were: decreased level of consciousness, hemiparesis and neurocognitive dysfunction. In the cerebral spinal fluid, protein was elevated in 22% of patients. The pattern of lesions was bilateral in 67% and multifocal in 55%, being suggestive of ischemic lesions by CNS magnetic resonance in 78% of the cases. The MRA was conclusive in all cases of secondary and normal in only one case of primary CNS angiitis. Increased erythrocyte sedimentation rate, C-reactive protein and leukocyte count were more frequently observed in patients with secondary CNS angiitis as compared to patients with primary angiitis. In one case of primary CNS angiitis with negative vascular study, the Von Willebrand factor antigen was positive, being useful in the differential diagnosis. Steroids were administered in 100% of patients, associated with immunosuppressants in 7/9 cases. Induction therapy with intravenous cyclophosphamide was used in 78% of the cases and in the maintenance phase, azathioprine in 78% of them. No relapses occurred. The most commonly clinical sequel observed was residual epilepsy (55%).

Conclusion: In this study, seizures were the most frequently symptom found. Steroids plus immunosuppressants were effective in the disease control. MRA was positive in all cases of secondary CNS angiitis, being effective in the diagnosis of this condition. Recognition of findings and adequate diagnosis guides the treatment, which should be specific to the underlying cause, aiming to provide a good neurologic outcome.

REFERENCES


PENTRA Xin 3 A MARKER OF DISEASE ACTIVITY IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS

Waled Hassan1, Eman Behiry2, Shorouk Abdelshafy3. 1Benha University, Rheumatology and Rehabilitation, Benha, Egypt; 2Benha University, Clinical and Chemical Pathology, Benha, Egypt; 3Benha University, Diagnostic Radiology, Benha, Egypt

Background: Pentraxin-3 (PTX3) is a secretory acute phase protein which is produced and expressed in many immune cells especially macrophages, fibroblasts and endothelial cells at different inflammatory sites [1].